Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17335961 | 0.88 | HPGD (0.49) | HPGDACHEALDH1A1NPSR1HSD17B10 | |
| SCHEMBL17347951 | 0.88 | HPGD (0.49) | HPGDACHEMETAP2 | |
| SCHEMBL17335984 | 0.81 | HPGD (0.55) | HPGDACHEALDH1A1NPSR1HSD17B10 | |
| SCHEMBL17335940 | 0.81 | HPGD (0.55) | HPGDACHEALDH1A1NPSR1HSD17B10 | |
| SCHEMBL17335942 | 0.80 | BRD4 (0.58) | HPGD | |
| SCHEMBL10084674 | 0.79 | HPGD (0.53) | HPGDACHEALDH1A1NPSR1HSD17B10 | |
| SCHEMBL17335941 | 0.76 | HPGD (0.50) | HPGDACHEALDH1A1NPSR1HSD17B10 | |
| SCHEMBL17335950 | 0.75 | ERCC1 (0.58) | HPGDACHEALDH1A1NPSR1HSD17B10 | |
| SCHEMBL17347739 | 0.74 | ERCC1 (0.59) | HPGDACHEALDH1A1NPSR1HSD17B10 | |
| SCHEMBL17335963 | 0.74 | HPGD (0.47) | HPGDACHEALDH1A1NPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015189595-A1 | TREATMENT OF CHAGAS DISEASE | UNIVERSITY OF DUNDEE (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | CXCR4, CBR1, CHRM1 | HPGD 3131/4885ACHE 772/4885METAP2 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.